Bright Minds Biosciences Inc (DRUG) Actualités

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

– Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O'Brien, MD; Jo Sourbron, MD, PhD, MPharm; and...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

NEW YORK and VANCOUVER, British Columbia, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc...

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form F-3 - Registration statement by foreign private issuers

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

-  Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data  ...

Form D - Notice of Exempt Offering of Securities

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]